Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism
(VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large …

Objectives: In the RE-COVER™ and RE-COVER™ II trials, dabigatran etexilate (DE)
compared with warfarin in patients with acute venous thromboembolism (VTE) resulted in …

Background Dabigatran, which is administered in a fixed dose and does not require
laboratory monitoring, may be suitable for extended treatment of venous thromboembolism …

Dabigatran was as effective as warfarin for the acute treatment of venous thromboembolism
in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with …

The relative efficacy and safety of dabigatran etexilate and warfarin have been evaluated in
two head-to-head, phase III, treatment of acute venous thromboembolism (VTE) trials, and …

Background—Dabigatran and warfarin have been compared for the treatment of acute
venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those …

Background The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant
effect and may be an alternative therapy to warfarin for patients who have acute venous …

Abstract Background In the RE-COVER and RE-COVER II trials, a fixed dose of dabigatran
etexilate was as effective as warfarin for prevention of recurrent VTE and was associated …

It is unclear whether thrombophilia causes resistance to anticoagulant therapy. Post hoc
analyses of data from RE-COVER®, RE-COVER™ II, and RE-MEDY™ were performed to …

Abstract Abstract 205 Background: Dabigatran has been compared with warfarin for
treatment of acute venous thromboembolism in one previous trial (RE-COVER). Based on …